{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T18:23:48Z","timestamp":1782843828136,"version":"3.54.5"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T00:00:00Z","timestamp":1705363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T00:00:00Z","timestamp":1705363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81970617"],"award-info":[{"award-number":["81970617"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005047","name":"Natural Science Foundation of Liaoning Province","doi-asserted-by":"publisher","award":["2019-MS-367"],"award-info":[{"award-number":["2019-MS-367"]}],"id":[{"id":"10.13039\/501100005047","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Special fund for clinical research of Chinese Medical Association","award":["18020060785"],"award-info":[{"award-number":["18020060785"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To date, our understanding of IgA nephropathy (IgAN) pathophysiology has remained incomplete; therefore, treatment remains largely empiric, and the efficacy and safety of immunosuppressants remain controversial. We aimed to assess the efficacy and safety of hydroxychloroquine and leflunomide therapy in a retrospective cohort of\u00a0patients with IgAN.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We screened the IgAN registration database in our department, and a total of 159 kidney patients with biopsy-confirmed IgAN were enrolled, with 57 patients receiving hydroxychloroquine plus a renin-angiotensin system inhibitor (hydroxychloroquine group), 52 patients receiving leflunomide plus a renin-angiotensin system inhibitor (leflunomide group), and 50 patients receiving only a renin-angiotensin system inhibitor (renin-angiotensin system inhibitor-only group). Changes in proteinuria, hematuria, and the estimated glomerular filtration rate (eGFR), as well as adverse events, were analyzed during the follow-up period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      At the end of 6-month follow-up, proteinuria significantly decreased by 70.36 (57.54, 79.33)%, 57.29 (46.79, 67.29)% and 41.20 (25.76, 48.94)% in the hydroxychloroquine, leflunomide and renin-angiotensin system inhibitor-only groups, respectively, compared to baseline (all\n                      <jats:italic>P<\/jats:italic>\n                      values\u2009&lt;\u20090.001). Hematuria significantly decreased by 71.07 (56.48, 82.47)% in the leflunomide group (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001). The eGFR improved by 3.72\u2009\u00b1\u20092.97%, 3.16\u2009\u00b1\u20092.00% and 1.91\u2009\u00b1\u20092.41%, respectively, in the hydroxychloroquine, leflunomide and renin-angiotensin system inhibitor-only groups, but without statistical significance. No serious adverse events occurred during the follow-up period.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Both hydroxychloroquine combined with a renin-angiotensin system inhibitor and leflunomide combined with a renin-angiotensin system inhibitor were more effective than a renin-angiotensin system inhibitor alone in improving proteinuria in IgAN patients. Hydroxychloroquine was more effective in reducing proteinuria, and leflunomide showed superiority in reducing hematuria. Our results need to be verified in large-scale randomized controlled trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s40620-023-01839-x","type":"journal-article","created":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T22:01:52Z","timestamp":1705356112000},"page":"933-940","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The efficacy and safety of hydroxychloroquine versus leflunomide in patients with IgA nephropathy: a single-center experience"],"prefix":"10.1093","volume":"37","author":[{"given":"Wei-jie","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gu-yue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-wang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5283-8636","authenticated-orcid":false,"given":"Lin-lin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,1,16]]},"reference":[{"key":"1839_CR1","doi-asserted-by":"publisher","first-page":"727","DOI":"10.2215\/cjn.0000000000000135","volume":"18","author":"D Pitcher","year":"2023","unstructured":"Pitcher D, Braddon F, Hendry B et al (2023) Long-term outcomes in IgA nephropathy. Clin J Am Soc Nephrol 18:727\u2013738. https:\/\/doi.org\/10.2215\/cjn.0000000000000135","journal-title":"Clin J Am Soc Nephrol"},{"key":"1839_CR2","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.3949\/ccjm.90.e-s1.02","volume":"90","author":"JJ Taliercio","year":"2023","unstructured":"Taliercio JJ, Mehdi A (2023) IgA nephropathy. Cleve Clin J Med 90:e5\u2013e8. https:\/\/doi.org\/10.3949\/ccjm.90.e-s1.02","journal-title":"Cleve Clin J Med"},{"key":"1839_CR3","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s40620-015-0248-3","volume":"29","author":"C Pozzi","year":"2016","unstructured":"Pozzi C (2016) Treatment of IgA nephropathy. J Nephrol 29:21\u201325. https:\/\/doi.org\/10.1007\/s40620-015-0248-3","journal-title":"J Nephrol"},{"key":"1839_CR4","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1001\/jama.2011.1141","volume":"306","author":"A Vivante","year":"2011","unstructured":"Vivante A, Afek A, Frenkel-Nir Y et al (2011) Persistent asymptomatic isolated microscopic hematuria in Israeli adolescents and young adults and risk for end-stage renal disease. JAMA 306:729\u2013736. https:\/\/doi.org\/10.1001\/jama.2011.1141","journal-title":"JAMA"},{"key":"1839_CR5","doi-asserted-by":"publisher","first-page":"16001","DOI":"10.1038\/nrdp.2016.1","volume":"2","author":"KN Lai","year":"2016","unstructured":"Lai KN, Tang SC, Schena FP et al (2016) IgA nephropathy. Nat Rev Dis Primers 2:16001. https:\/\/doi.org\/10.1038\/nrdp.2016.1","journal-title":"Nat Rev Dis Primers"},{"key":"1839_CR6","doi-asserted-by":"publisher","first-page":"7309","DOI":"10.1038\/s41598-018-25653-9","volume":"8","author":"LL Liu","year":"2018","unstructured":"Liu LL, Zhu LB, Zheng JN et al (2018) Development and assessment of a predictive nomogram for the progression of IgA nephropathy. Sci Rep 8:7309. https:\/\/doi.org\/10.1038\/s41598-018-25653-9","journal-title":"Sci Rep"},{"key":"1839_CR7","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.kint.2017.02.003","volume":"91","author":"H Trimarchi","year":"2017","unstructured":"Trimarchi H, Barratt J, Cattran DC et al (2017) Oxford classification of IgA nephropathy 2016: an update from the IgA nephropathy classification working group. Kidney Int 91:1014\u20131021. https:\/\/doi.org\/10.1016\/j.kint.2017.02.003","journal-title":"Kidney Int"},{"key":"1839_CR8","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1001\/jama.2017.9362","volume":"318","author":"J Lv","year":"2017","unstructured":"Lv J, Zhang H, Wong MG et al (2017) Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA 318:432\u2013442. https:\/\/doi.org\/10.1001\/jama.2017.9362","journal-title":"JAMA"},{"key":"1839_CR9","doi-asserted-by":"publisher","first-page":"Cd003965","DOI":"10.1002\/14651858.CD003965.pub3","volume":"3","author":"P Natale","year":"2020","unstructured":"Natale P, Palmer SC, Ruospo M et al (2020) Immunosuppressive agents for treating IgA nephropathy. Cochrane Database Syst Rev 3:Cd003965. https:\/\/doi.org\/10.1002\/14651858.CD003965.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"1839_CR10","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s00281-021-00888-3","volume":"43","author":"J Floege","year":"2021","unstructured":"Floege J, Rauen T, Tang SCW (2021) Current treatment of IgA nephropathy. Semin Immunopathol 43:717\u2013728. https:\/\/doi.org\/10.1007\/s00281-021-00888-3","journal-title":"Semin Immunopathol"},{"key":"1839_CR11","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1136\/annrheumdis-2017-211836","volume":"77","author":"C Rempenault","year":"2018","unstructured":"Rempenault C, Combe B, Barnetche T et al (2018) Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis 77:98\u2013103. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211836","journal-title":"Ann Rheum Dis"},{"key":"1839_CR12","doi-asserted-by":"publisher","first-page":"3263","DOI":"10.1182\/blood-2011-01-329060","volume":"118","author":"S Piconi","year":"2011","unstructured":"Piconi S, Parisotto S, Rizzardini G et al (2011) Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders. Blood 118:3263\u20133272. https:\/\/doi.org\/10.1182\/blood-2011-01-329060","journal-title":"Blood"},{"key":"1839_CR13","doi-asserted-by":"publisher","first-page":"R155","DOI":"10.1186\/ar3895","volume":"14","author":"K Sacre","year":"2012","unstructured":"Sacre K, Criswell LA, McCune JM (2012) Hydroxychloroquine is associated with impaired interferon-alpha and tumor necrosis factor-alpha production by plasmacytoid dendritic cells in systemic lupus erythematosus. Arthritis Res Ther 14:R155. https:\/\/doi.org\/10.1186\/ar3895","journal-title":"Arthritis Res Ther"},{"key":"1839_CR14","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.kint.2019.08.022","volume":"97","author":"Y Makita","year":"2020","unstructured":"Makita Y, Suzuki H, Kano T et al (2020) TLR9 activation induces aberrant IgA glycosylation via APRIL- and IL-6-mediated pathways in IgA nephropathy. Kidney Int 97:340\u2013349. https:\/\/doi.org\/10.1016\/j.kint.2019.08.022","journal-title":"Kidney Int"},{"key":"1839_CR15","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1186\/s12882-019-1488-6","volume":"20","author":"YZ Yang","year":"2019","unstructured":"Yang YZ, Chen P, Liu LJ et al (2019) Comparison of the effects of hydroxychloroquine and corticosteroid treatment on proteinuria in IgA nephropathy: a case-control study. BMC Nephrol 20:297. https:\/\/doi.org\/10.1186\/s12882-019-1488-6","journal-title":"BMC Nephrol"},{"key":"1839_CR16","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1080\/0886022X.2021.2000875","volume":"43","author":"G Stefan","year":"2021","unstructured":"Stefan G, Mircescu G (2021) Hydroxychloroquine in IgA nephropathy: a systematic review. Ren Fail 43:1520\u20131527. https:\/\/doi.org\/10.1080\/0886022X.2021.2000875","journal-title":"Ren Fail"},{"key":"1839_CR17","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s40620-021-00988-1","volume":"35","author":"C Tang","year":"2022","unstructured":"Tang C, Lv JC, Shi SF et al (2022) Long-term safety and efficacy of hydroxychloroquine in patients with IgA nephropathy: a single-center experience. J Nephrol 35:429\u2013440. https:\/\/doi.org\/10.1007\/s40620-021-00988-1","journal-title":"J Nephrol"},{"key":"1839_CR18","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1136\/ard.59.11.841","volume":"59","author":"FC Breedveld","year":"2000","unstructured":"Breedveld FC, Dayer JM (2000) Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann Rheum Dis 59:841\u2013849. https:\/\/doi.org\/10.1136\/ard.59.11.841","journal-title":"Ann Rheum Dis"},{"key":"1839_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102960","volume":"21","author":"I Carri\u00f3n-Barber\u00e0","year":"2022","unstructured":"Carri\u00f3n-Barber\u00e0 I, Polino L, Mej\u00eda-Torres M et al (2022) Leflunomide: a safe and effective alternative in systemic lupus erythematosus. Autoimmun Rev 21:102960. https:\/\/doi.org\/10.1016\/j.autrev.2021.102960","journal-title":"Autoimmun Rev"},{"key":"1839_CR20","doi-asserted-by":"publisher","first-page":"48375","DOI":"10.18632\/oncotarget.16468","volume":"8","author":"L Min","year":"2017","unstructured":"Min L, Wang Q, Cao L et al (2017) Comparison of combined leflunomide and low-dose corticosteroid therapy with full-dose corticosteroid monotherapy for progressive IgA nephropathy. Oncotarget 8:48375\u201348384. https:\/\/doi.org\/10.18632\/oncotarget.16468","journal-title":"Oncotarget"},{"key":"1839_CR21","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1080\/0886022x.2021.1963775","volume":"43","author":"Z Ni","year":"2021","unstructured":"Ni Z, Zhang Z, Yu Z et al (2021) Leflunomide plus low-dose prednisone in patients with progressive IgA nephropathy: a multicenter, prospective, randomized, open-labeled, and controlled trial. Ren Fail 43:1214\u20131221. https:\/\/doi.org\/10.1080\/0886022x.2021.1963775","journal-title":"Ren Fail"},{"key":"1839_CR22","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1053\/j.ajkd.2019.01.026","volume":"74","author":"LJ Liu","year":"2019","unstructured":"Liu LJ, Yang YZ, Shi SF et al (2019) Effects of hydroxychloroquine on proteinuria in IgA nephropathy: a randomized controlled trial. Am J Kidney Dis 74:15\u201322. https:\/\/doi.org\/10.1053\/j.ajkd.2019.01.026","journal-title":"Am J Kidney Dis"},{"key":"1839_CR23","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/nep.12359","volume":"20","author":"G Cheng","year":"2015","unstructured":"Cheng G, Liu D, Margetts P et al (2015) Valsartan combined with clopidogrel and\/or leflunomide for the treatment of progressive immunoglobulin A nephropathy. Nephrology (Carlton) 20:77\u201384. https:\/\/doi.org\/10.1111\/nep.12359","journal-title":"Nephrology (Carlton)"},{"key":"1839_CR24","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1136\/ard-2022-222486","volume":"81","author":"Q Fu","year":"2022","unstructured":"Fu Q, Wu C, Dai M et al (2022) Leflunomide versus azathioprine for maintenance therapy of lupus nephritis: a prospective, multicentre, randomised trial and long-term follow-up. Ann Rheum Dis 81:1549\u20131555. https:\/\/doi.org\/10.1136\/ard-2022-222486","journal-title":"Ann Rheum Dis"},{"key":"1839_CR25","doi-asserted-by":"publisher","first-page":"4794","DOI":"10.4049\/jimmunol.1000702","volume":"186","author":"A Kuznik","year":"2011","unstructured":"Kuznik A, Bencina M, Svajger U et al (2011) Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J Immunol 186:4794\u20134804. https:\/\/doi.org\/10.4049\/jimmunol.1000702","journal-title":"J Immunol"},{"key":"1839_CR26","first-page":"55","volume":"24","author":"BE van den Borne","year":"1997","unstructured":"van den Borne BE, Dijkmans BA, de Rooij HH et al (1997) Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma production by peripheral blood mononuclear cells. J Rheumatol 24:55\u201360","journal-title":"J Rheumatol"},{"key":"1839_CR27","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1097\/01.asn.0000115401.07980.0c","volume":"15","author":"IC Moura","year":"2004","unstructured":"Moura IC, Arcos-Fajardo M, Sadaka C et al (2004) Glycosylation and size of IgA1 are essential for interaction with mesangial transferrin receptor in IgA nephropathy. J Am Soc Nephrol 15:622\u2013634. https:\/\/doi.org\/10.1097\/01.asn.0000115401.07980.0c","journal-title":"J Am Soc Nephrol"},{"key":"1839_CR28","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1111\/j.1523-1755.2005.67107.x","volume":"67","author":"J Novak","year":"2005","unstructured":"Novak J, Tomana M, Matousovic K et al (2005) IgA1-containing immune complexes in IgA nephropathy differentially affect proliferation of mesangial cells. Kidney Int 67:504\u2013513. https:\/\/doi.org\/10.1111\/j.1523-1755.2005.67107.x","journal-title":"Kidney Int"},{"key":"1839_CR29","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s40620-015-0247-4","volume":"29","author":"S Feriozzi","year":"2016","unstructured":"Feriozzi S, Polci R (2016) The role of tonsillectomy in IgA nephropathy. J Nephrol 29:13\u201319. https:\/\/doi.org\/10.1007\/s40620-015-0247-4","journal-title":"J Nephrol"},{"key":"1839_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2019.08.021","volume":"169","author":"L Bai","year":"2019","unstructured":"Bai L, Li J, Li H et al (2019) Renoprotective effects of artemisinin and hydroxychloroquine combination therapy on IgA nephropathy via suppressing NF-\u03baB signaling and NLRP3 inflammasome activation by exosomes in rats. Biochem Pharmacol 169:113619. https:\/\/doi.org\/10.1016\/j.bcp.2019.08.021","journal-title":"Biochem Pharmacol"},{"key":"1839_CR31","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1007\/s00467-005-1915-8","volume":"20","author":"YH Park","year":"2005","unstructured":"Park YH, Choi JY, Chung HS et al (2005) Hematuria and proteinuria in a mass school urine screening test. Pediatr Nephrol 20:1126\u20131130. https:\/\/doi.org\/10.1007\/s00467-005-1915-8","journal-title":"Pediatr Nephrol"},{"key":"1839_CR32","first-page":"251","volume":"16","author":"G D'Amico","year":"1981","unstructured":"D\u2019Amico G, Ferrario F, Colasanti G et al (1981) IgA-mesangial nephropathy (Berger\u2019s disease) with rapid decline in renal function. Clin Nephrol 16:251\u2013257","journal-title":"Clin Nephrol"},{"key":"1839_CR33","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1053\/j.ajkd.2019.11.008","volume":"76","author":"GZ Yu","year":"2020","unstructured":"Yu GZ, Guo L, Dong JF et al (2020) Persistent hematuria and kidney disease progression in IgA nephropathy: a cohort study. Am J Kidney Dis 76:90\u201399. https:\/\/doi.org\/10.1053\/j.ajkd.2019.11.008","journal-title":"Am J Kidney Dis"},{"key":"1839_CR34","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.1681\/asn.2017010108","volume":"28","author":"AM Sevillano","year":"2017","unstructured":"Sevillano AM, Guti\u00e9rrez E, Yuste C et al (2017) Remission of hematuria improves renal survival in IgA nephropathy. J Am Soc Nephrol 28:3089\u20133099. https:\/\/doi.org\/10.1681\/asn.2017010108","journal-title":"J Am Soc Nephrol"},{"key":"1839_CR35","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1053\/j.ajkd.2022.02.022","volume":"80","author":"MK Saha","year":"2022","unstructured":"Saha MK, Massicotte-Azarniouch D, Reynolds ML et al (2022) Glomerular hematuria and the utility of urine microscopy: a review. Am J Kidney Dis 80:383\u2013392. https:\/\/doi.org\/10.1053\/j.ajkd.2022.02.022","journal-title":"Am J Kidney Dis"},{"key":"1839_CR36","doi-asserted-by":"publisher","first-page":"5962","DOI":"10.4049\/jimmunol.165.10.5962","volume":"165","author":"SK Manna","year":"2000","unstructured":"Manna SK, Mukhopadhyay A, Aggarwal BB (2000) Leflunomide suppresses TNF-induced cellular responses: effects on NF-kappa B, activator protein-1, c-Jun N-terminal protein kinase, and apoptosis. J Immunol 165:5962\u20135969. https:\/\/doi.org\/10.4049\/jimmunol.165.10.5962","journal-title":"J Immunol"},{"key":"1839_CR37","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1046\/j.1523-1755.2001.00941.x","volume":"60","author":"SA Mezzano","year":"2001","unstructured":"Mezzano SA, Barr\u00eda M, Droguett MA et al (2001) Tubular NF-kappaB and AP-1 activation in human proteinuric renal disease. Kidney Int 60:1366\u20131377. https:\/\/doi.org\/10.1046\/j.1523-1755.2001.00941.x","journal-title":"Kidney Int"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-023-01839-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40620-023-01839-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-023-01839-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:54:00Z","timestamp":1777564440000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/37\/4\/933\/8306791"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,16]]},"references-count":37,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["1839"],"URL":"https:\/\/doi.org\/10.1007\/s40620-023-01839-x","relation":{},"ISSN":["1724-6059"],"issn-type":[{"value":"1724-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,16]]},"assertion":[{"value":"18 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None of the authors has any potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Our study was performed in compliance with the principles of the Declaration of Helsinki and was approved by the Ethics Committee and the Research Board of the First Affiliated Hospital of China Medical University (AF-SOP-07-1 1-01).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from the participants in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}